In addition, significantly lower levels of TSPAN32 were found in PBMCs from MS patients developing exacerbation of the disease before 300 days as compared with patients who underwent relapses later than 1500 days (Figure 5D). Here, TSPAN32 is linked to myeloid sarcoma.